Rituximab treatment results in impaired secondary humoral immune responsiveness

This publication has 12 references indexed in Scilit:

• Rituximab: perspective on single agent experience, and future directions in combination trials
  Critical Reviews in Oncology/Hematology, 2001
• Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease
  Annals of Internal Medicine, 2000
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
  Journal of Clinical Oncology, 1998
• Humoral Immunity Due to Long-Lived Plasma Cells
  Immunity, 1998
• Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial
  Blood, 1997
• Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted
  Vaccine, 1994
• Measurement of primary in vivo IgM- and IgG-antibody response to KLH in humans: Implications of pre-immune IgM binding in antigen-specific ELISA
  Journal of Immunological Methods, 1984
• Standardization of Poliovirus Neutralizing Antibody Tests
  Clinical Infectious Diseases, 1984
• Immune function of successfully treated lymphoma patients.
  Journal of Clinical Investigation, 1976
• Immunological responsiveness against two primary antigens in untreated patients with Hodgkin's disease
  European Journal of Cancer (1965), 1975